Cargando…
ONC201 Suppresses Neuroblastoma Growth by Interrupting Mitochondrial Function and Reactivating Nuclear ATRX Expression While Decreasing MYCN
Neuroblastoma (NB) is characterized by several malignant phenotypes that are difficult to treat effectively without combination therapy. The therapeutic implication of mitochondrial ClpXP protease ClpP and ClpX has been verified in several malignancies, but is unknown in NB. Firstly, we observed a s...
Autores principales: | Wu, Jian-Ching, Huang, Chao-Cheng, Wang, Pei-Wen, Chen, Ting-Ya, Hsu, Wen-Ming, Chuang, Jiin-Haur, Chuang, Hui-Ching |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867473/ https://www.ncbi.nlm.nih.gov/pubmed/36675163 http://dx.doi.org/10.3390/ijms24021649 |
Ejemplares similares
-
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020) -
A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins
por: El-Soussi, Sarra, et al.
Publicado: (2021) -
MDA5 complements TLR3 in suppression of neuroblastoma
por: Hsu, Wen-Ming, et al.
Publicado: (2015) -
5-aza-2′-Deoxycytidine Induces a RIG-I-Related Innate Immune Response by Modulating Mitochondria Stress in Neuroblastoma
por: Lin, Hung-Yu, et al.
Publicado: (2020) -
Innate immune sensor laboratory of genetics and physiology 2 suppresses tumor cell growth and functions as a prognostic marker in neuroblastoma
por: Lin, Li‐Ling, et al.
Publicado: (2018)